insights_auto
为什么 TRVN 下跌了 99.24%?
深入探索chevron_right
TRVN:OTCMKTS
Trevena Inc
US$0.00050
arrow_downward
-99.24%(-0.066) 1 天
10月16日, GMT-4 16:00:00 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 TRVN 生成关键数据洞见…
开盘价
US$0.00
最高价
US$0.00
最低价
US$0.00
市值
407.21
平均成交量
210.00
成交量
4129.00
52 周最高价
US$1.50
52 周最低价
US$0.00
Beta 版
1.07
流通股数
86.40万
员工人数
23
开盘价
US$0.00
最高价
US$0.00
最低价
US$0.00
市值
407.21
平均成交量
210.00
成交量
4129.00
52 周最高价
US$1.50
52 周最低价
US$0.00
Beta 版
1.07
流通股数
86.40万
员工人数
23
新闻报道
来自网络来源和新闻合作伙伴
资料
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Trevena Inc简介